JP2001302529A - Bile acid production promoter and food and drink - Google Patents
Bile acid production promoter and food and drinkInfo
- Publication number
- JP2001302529A JP2001302529A JP2000120598A JP2000120598A JP2001302529A JP 2001302529 A JP2001302529 A JP 2001302529A JP 2000120598 A JP2000120598 A JP 2000120598A JP 2000120598 A JP2000120598 A JP 2000120598A JP 2001302529 A JP2001302529 A JP 2001302529A
- Authority
- JP
- Japan
- Prior art keywords
- tea
- bile acid
- bile
- acid production
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Tea And Coffee (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
(57)【要約】
【課題】 本発明は、天然物由来の物質を有効成分とす
る胆汁酸生成促進組成剤及び飲食物を提供せんとする。
【解決手段】 茶を温水又は熱水で抽出して得られる茶
抽出物、例えば茶カテキン、テアフラビン、テアルビジ
ン等の茶ポリフェノールを有効成分とする胆汁酸生成促
進剤及び飲食物を作成した。体内に摂取することによっ
て肝臓における胆汁酸の生成を促進させることができ、
胆汁酸の分泌の減少に伴なう消化不良や栄養源の欠乏な
どの症状に効果を発揮する。更に、血中コレステロール
濃度をコントールすることができ、血中コレステロール
が高いことに起因する疾患例えば動脈硬化や大腸ガンな
どの疾患の治療及び予防に効果を発揮するものと期待で
きる。PROBLEM TO BE SOLVED: To provide a composition for promoting bile acid production and a food or drink comprising a substance derived from a natural product as an active ingredient. SOLUTION: A tea extract obtained by extracting tea with warm water or hot water, for example, a bile acid production promoter and a food and drink containing a tea polyphenol such as tea catechin, theaflavin, and thealvidin as an active ingredient are prepared. By ingesting into the body can promote the production of bile acids in the liver,
It is effective for symptoms such as dyspepsia and lack of nutrients caused by decreased secretion of bile acids. Furthermore, it can control blood cholesterol concentration, and is expected to be effective in treating and preventing diseases caused by high blood cholesterol such as arteriosclerosis and colorectal cancer.
Description
【0001】[0001]
【産業上の利用分野】本発明は、胆汁酸や胆汁色素など
の胆汁成分の生成を促進する胆汁酸生成促進組成剤及び
飲食物に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition for promoting bile acid production which promotes the production of bile components such as bile acids and bile pigments, and a food and drink.
【0002】[0002]
【従来の技術及び発明が解決しようとする課題】胆汁酸
(ステロイド系カルボキシル酸の総称;本発明では当該
酸の塩も包含する意味で用いる。)は、胆汁の主成分の
ひとつで、肝臓においてコレステロールから生成され、
そのほとんどがグリシンやタウリンと抱合してグリココ
ール酸やタウロコール酸となり胆嚢に貯蔵される。ちな
みに、胆嚢に貯蔵された胆汁酸は、食物を口に含む等に
よって胆嚢が収縮すると総胆管を経て胆汁として十二指
腸に分泌され、食物と混ざった後、腸から再び吸収さ
れ、門脈を経て肝臓に戻り、再び胆汁として分泌される
こととなる(胆汁酸の腸肝循環)。2. Description of the Related Art Bile acids (generic term for steroidal carboxylic acids; used in the present invention to include salts of the acids) are one of the main components of bile and are used in the liver. Produced from cholesterol,
Most of them are conjugated with glycine and taurine to become glycocholate and taurocholate, which are stored in the gallbladder. By the way, bile acids stored in the gall bladder are secreted into the duodenum as bile through the common bile duct when the gall bladder contracts due to the inclusion of food in the mouth, etc., mixed with food, then reabsorbed from the intestine, and passed through the portal vein to the liver. And is again secreted as bile (enterohepatic circulation of bile acids).
【0003】この胆汁酸は、表面活性作用が強く、ミセ
ルを形成してこのミセル内部にコレステロールや長鎖脂
肪酸を取り込むことができる。食事として摂取した脂質
の消化・吸収を助ける働きや、コレステロール値を一定
に保つ働きは、胆汁酸の最も重要な役割である。胆汁酸
は、このほかにも体内の消化活動に様々に影響し、食物
の消化・吸収に重大な役割を果たしている。また最近で
は、胆汁酸の全く新しい働きとして、胆汁酸が核内受容
体のリガンド(配位子)として作用し,遺伝子の転写を
直接調節する効果があることも分かってきた。すなわ
ち、胆汁酸(ケノデオキシコール酸)の核内受容体の1
つであるFXR(fornesoid X receptor)が、ケノデオ
キシコール酸の結合によりコレステロールから胆汁酸を
合成する律速酵素の遺伝子の転写を抑制する一方、小腸
での胆汁酸の再吸収にかかわる胆汁酸結合タンパクの遺
伝子の転写を促進し、体内コレステロール値の恒常性調
節機構に寄与していることが報告されている(Parks,
D. J. et al. : Science, 284 : 1365-1368, 1999、Wan
g, H. et al. : Mol. Cell, 3 : 543-553, 1999)。[0003] This bile acid has a strong surface activity and can form micelles and take up cholesterol and long-chain fatty acids into the micelles. The role of bile acids in assisting digestion and absorption of dietary lipids and maintaining a constant cholesterol level is the most important role of bile acids. Bile acids also have various effects on the digestive activity of the body and play a significant role in the digestion and absorption of food. Recently, as a completely new function of bile acids, it has been found that bile acids act as ligands for nuclear receptors and have the effect of directly regulating gene transcription. That is, one of the nuclear receptors of bile acid (chenodeoxycholic acid)
FXR (fornesoid X receptor) suppresses the transcription of the rate-limiting enzyme that synthesizes bile acid from cholesterol by binding to chenodeoxycholic acid, and the gene for the bile acid-binding protein involved in bile acid reabsorption in the small intestine Has been reported to promote the transcription of cholesterol and contribute to the regulation of cholesterol levels in the body (Parks,
DJ et al .: Science, 284: 1365-1368, 1999, Wan
g, H. et al .: Mol. Cell, 3: 543-553, 1999).
【0004】このように胆汁酸は体内において重要な役
割を果たしているため、胆汁酸の分泌が減少すると、消
化不良、栄養源の欠乏、血中コレステロール濃度の上昇
などの様々な症状が見られるようになる。そこで従来か
ら、胆汁酸の分泌が減少した場合に胆汁酸の分泌を促す
物質、すなわち有用で安全な胆汁酸利胆剤の開発が望ま
れていた。[0004] Since bile acids play an important role in the body as described above, various symptoms such as indigestion, lack of nutrient sources, and elevated blood cholesterol level may be observed when secretion of bile acids is reduced. become. Therefore, conventionally, there has been a demand for the development of a substance that stimulates the secretion of bile acids when the secretion of bile acids decreases, that is, a useful and safe bile acid bile agent.
【0005】従来、コレスチラミンやコレスチポールに
代表されるアニオン交換樹脂、動物繊維のキチンの脱ア
セチル化物であるキトサン等には胆汁酸生成促進効果が
認められていた。胆汁酸利胆剤としては、ウルソサン
(UDCA:Ursodesoxycholic acid)やケノコール
(CDCA:chenodeoxycholic acid)等が実際に使用
されており、中でもウルソサンは、有害な胆汁酸の除去
にも役立つ点から、慢性肝炎、原発性胆汁性肝硬変、ウ
ィルス性或いは薬物性の肝障害で遅延する肝内胆汁うっ
滞の治療にも用いられている。Conventionally, an anion exchange resin represented by cholestyramine and colestipol, chitosan which is a deacetylated product of chitin of animal fiber, and the like have been found to have a bile acid production promoting effect. As bile acid bile agents, ursosan (UDCA: Ursodesoxycholic acid), chenocole (CDCA: chenodeoxycholic acid) and the like are actually used. Among them, ursosan is useful for removing harmful bile acids, and therefore chronic hepatitis. It is also used in the treatment of intrahepatic cholestasis delayed by primary biliary cirrhosis, viral or drug-induced liver injury.
【0006】本発明者らは、天然物由来の物質中にも胆
汁酸生成促進効果を奏する物質があるのではないかと考
え、鋭意研究した結果、遂に茶由来の成分に胆汁酸生成
促進効果を見出すことに成功し、かかる知見に基づいて
本発明を想到するに至った。[0006] The present inventors have considered that some substances derived from natural products may have a bile acid production promoting effect. They succeeded in finding the present invention and came to the present invention based on such knowledge.
【0007】[0007]
【課題を解決するための手段】本発明は、茶を抽出して
得られた茶抽出物を有効成分として含有する胆汁酸生成
促進剤及び飲食物である。ここで、茶抽出物とは茶を温
水や熱水などで抽出して得られた抽出物又はこの抽出物
を乾燥処理等して得られる抽出エキスを意味するもので
あるが、茶ポリフェノール中でもカテキンは本発明の有
効成分として特に好ましい。Means for Solving the Problems The present invention relates to a bile acid production promoter and a food or drink containing, as an active ingredient, a tea extract obtained by extracting tea. Here, the tea extract means an extract obtained by extracting tea with warm water or hot water or an extract obtained by subjecting the extract to a drying treatment or the like. Is particularly preferred as the active ingredient of the present invention.
【0008】本発明の胆汁酸生成促進剤及び飲食物は、
経口摂取等により体内に摂取することによって肝臓にお
ける胆汁酸の生成を促進させることができ、胆汁酸の分
泌の減少に伴なう消化不良や栄養源の欠乏などの症状に
効果を発揮するばかりか、血中コレステロール濃度をコ
ントールすることができ、血中コレステロールが高いこ
とに起因する疾患例えば動脈硬化や大腸ガンなどの疾患
の治療及び予防に効果を発揮するものと期待できる。ま
た、胆汁酸利胆剤として、胆道(胆管や胆のう)系疾患
や胆汁うつ滞を伴う肝疾患、高トリグリセリド血症、胆
石、及び小腸切除後遺症・炎症性小腸疾患における消化
不良など、様々な肝機能疾患の治療や予防に効果を発揮
するものと期待できる。しかも、本発明は昔から常用さ
れている茶から抽出される成分を有効成分とするもので
あるから、人体に対する安全性の点でも心配はない。[0008] The bile acid production promoter and food and drink of the present invention
By ingesting into the body by oral ingestion, etc., it can promote the production of bile acids in the liver, and not only exerts effects on symptoms such as indigestion and lack of nutrients due to decreased bile acid secretion It can control blood cholesterol concentration, and is expected to be effective in treating and preventing diseases caused by high blood cholesterol, such as arteriosclerosis and colorectal cancer. In addition, as a bile acid bile agent, various hepatic diseases such as biliary tract (bile duct and gall bladder) system disease, liver disease accompanied by bile depression, hypertriglyceridemia, gallstone, and indigestion in small bowel resection sequelae and inflammatory small bowel disease. It is expected to be effective in treating and preventing functional diseases. In addition, since the present invention uses an active ingredient extracted from tea that has been commonly used for a long time, there is no concern about the safety to the human body.
【0009】[0009]
【発明の実施の形態】上記の如く、本発明の胆汁酸生成
促進剤及び飲食物は、茶を抽出して得られた茶抽出物を
有効成分として含有するものである。BEST MODE FOR CARRYING OUT THE INVENTION As described above, the bile acid production promoter and the food and drink of the present invention contain a tea extract obtained by extracting tea as an active ingredient.
【0010】本発明における「茶」とは、ツバキ科に属
する茶樹(Camellia sinensis )から得られる葉、茎、
木部、根、実のいずれか、或いはこれらの2種類以上の
混合物を意味し、紅茶、プアール茶等の発酵茶、ウーロ
ン茶、包種茶等の半発酵茶、緑茶、釜煎り緑茶、ほうじ
茶等の不発酵茶のいずれであってもよいし、また、これ
らの2種類以上の混合物であってもよい。In the present invention, "tea" refers to leaves, stems, and the like obtained from tea plants (Camellia sinensis) belonging to the family Camellia.
It means any of xylem, root, fruit, or a mixture of two or more of them. Fermented tea such as black tea, pual tea, oolong tea, semi-fermented tea such as wrapping tea, green tea, pot roasted green tea, roasted green tea, etc. May be used, and a mixture of two or more of these may be used.
【0011】茶抽出物としては、上記茶を、水、温水ま
たは熱水、好ましくは40℃〜100℃の温熱水中でも
90〜100℃の熱水にて抽出して得られた抽出物、更
に好ましくはこの抽出物を樹脂吸着や限外濾過・逆浸透
濾過等の濾過、或いは酢酸エチル等を使用した分配抽出
などの精製手段によって茶カテキン含有量を高める方向
に精製して得られる茶抽出物、或いは更にこれらの茶抽
出物を濃縮或いは乾燥させた茶抽出エキスを挙げること
ができる。具体的には、緑茶を熱水抽出処理し、この抽
出物を乾燥させて茶カテキン濃度を約30%とした緑茶
エキス(伊藤園社製商品名:テアフラン30A)や、緑
茶を熱水抽出処理し、この抽出物を茶カテキン以外の成
分を排除するためにカラム法により処理し乾燥させて、
茶カテキン濃度を約85%とした緑茶エキス(伊藤園社
製商品名:テアフラン90S)を例示することができ
る。これらは市販品であるから、茶カテキンを十分に含
有している上、入手しやすいという点で好適である。As the tea extract, an extract obtained by extracting the above tea with water, hot water or hot water, preferably in hot water of 40 to 100 ° C. with hot water of 90 to 100 ° C., Preferably, the tea extract obtained by purifying this extract in a direction to increase the tea catechin content by purification means such as resin adsorption, filtration such as ultrafiltration, reverse osmosis filtration, or distribution extraction using ethyl acetate or the like. Alternatively, there may be mentioned a tea extract obtained by concentrating or drying these tea extracts. Specifically, green tea is subjected to hot water extraction treatment, and the extract is dried to obtain a green tea extract (trade name: Theafuran 30A, manufactured by ITO EN Co., Ltd.) having a tea catechin concentration of about 30%, or hot water extraction treatment for green tea. The extract was treated by a column method to remove components other than tea catechin and dried,
A green tea extract having a tea catechin concentration of about 85% (trade name: Theafran 90S, manufactured by Itoen Co., Ltd.) can be exemplified. Since these are commercially available products, they are suitable in that they contain tea catechins sufficiently and are easily available.
【0012】また、茶抽出物としては、カテキン、テア
フラビン、テアルビジンなどの茶ポリフェノール、その
中でも特にフラバン-3-オールの基本構造を有する次の
茶カテキン、すなわち (-)-エピカテキン(EC)、(-)-エ
ピガロカテキン(EGC)、(-)-エピカテキンガレート(EC
G)、(-)-エピガロカテキンガレート(EGCG)、さらにその
異性体である(±)-カテキン(C)、(-)-ガロカテキン(G
C)、(-)-カテキンガレート(CG)、(-)-ガロカテキンガレ
ート(GCG)のいずれか、或いはこれらの2種類以上を組み
合わせて混合してなるものは、本発明の有効成分として
好ましく使用することができる。[0012] Examples of the tea extract include tea polyphenols such as catechin, theaflavin and thealvidin, among which the following tea catechins having a basic structure of flavan-3-ol, namely, (-)-epicatechin (EC), (-)-Epigallocatechin (EGC), (-)-Epicatechin gallate (EC
G), (-)-epigallocatechin gallate (EGCG), and its isomers (±) -catechin (C), (-)-gallocatechin (G
C), (-)-catechin gallate (CG), any one of (-)-gallocatechin gallate (GCG), or those obtained by mixing and mixing two or more thereof are preferable as the active ingredient of the present invention. Can be used.
【0013】上記の茶抽出物、茶ポリフェノール又はカ
テキンは、いずれもそれぞれ単独で本発明の有効成分を
構成することができるが、コレスチラミンやコレスチポ
ールに代表されるアニオン交換樹脂、キトサン、ウルソ
サン(UDCA:Ursodesoxycholic acid)やケノコー
ル(CDCA:chenodeoxycholic acid)等、既に胆汁
酸生成促進効果が認められた物質と組み合わせて有効成
分を構成するようにすれば一層の胆汁酸生成促進効果を
期待することができる。また、既にコレステロール低下
作用を有する食品(リノール酸などの多価不飽和脂肪
酸、食物繊維、レシチン、サポニン)や医薬品(プロブ
コール、メバロチン)等と組み合わせることによってコ
レステロール低下作用を一層高めることができるものと
期待することができる。The above-mentioned tea extract, tea polyphenol and catechin can each independently constitute the active ingredient of the present invention. Anion exchange resins such as cholestyramine and colestipol, chitosan and ursosan (UDCA) : Bile acid generation promoting effect can be expected if the active ingredient is composed in combination with a substance which has already been recognized as a bile acid generation promoting effect, such as ursodesoxycholic acid and kenochol (CDCA: chenodeoxycholic acid). . In addition, cholesterol-lowering action can be further enhanced by combining with foods that already have cholesterol-lowering action (polyunsaturated fatty acids such as linoleic acid, dietary fiber, lecithin, saponin) and pharmaceuticals (probucol, mevalotin). You can expect.
【0014】また、上記の茶抽出物、茶ポリフェノール
又はカテキン等は、医薬品、医薬部外品、化粧品、健康
食品や健康飲料などの医療効果を有する飲食物、食品添
加剤、飼料、飼料用添加剤などの有効成分として用いる
ことができ、使用形態としては、凍結乾燥或いは噴霧乾
燥等により乾燥させて乾燥粉末として提供することも、
液剤、錠剤、散剤、顆粒、糖衣錠、カプセル、懸濁液、
乳剤、アンプル剤、注射剤等として提供することもでき
る。例えば、医薬部外品として調整し、これを瓶ドリン
ク飲料等の飲用形態、或いはタブレット、カプセル、顆
粒等の摂取し易い形態として提供すれば、日常的に摂取
することにより生体に対して十分な薬理効果をもたらす
ことができる。The above-mentioned tea extract, tea polyphenol, catechin, etc. are used for foods and drinks, food additives, feeds, feeds, etc. having medical effects such as pharmaceuticals, quasi-drugs, cosmetics, health foods and health drinks. It can be used as an active ingredient such as an agent, and as a use form, it can be provided as a dry powder by drying by freeze drying or spray drying,
Solutions, tablets, powders, granules, dragees, capsules, suspensions,
It can also be provided as an emulsion, ampoule, injection, or the like. For example, if prepared as a quasi-drug and provided in a drinkable form such as a bottled drink or in an easy-to-take form such as tablets, capsules, granules, etc., it is sufficient for a living body by taking it daily. Can produce pharmacological effects.
【0015】本発明における有効成分の含有量は、用途
によっても異なるが、医薬品であれば、カテキン乾燥重
量換算にして0.001〜1重量%、特に0.01〜0.
5重量%配合することが好ましい。摂取量としては、カ
テキン乾燥重量換算で一日に10〜5000mg、好ましくは50
0〜1000mg程度が好ましい。Although the content of the active ingredient in the present invention varies depending on the use, it is 0.001 to 1% by weight, particularly 0.01 to 0.1% by weight in terms of catechin dry weight in the case of pharmaceuticals.
It is preferable to mix 5% by weight. As the intake amount, 10 to 5000 mg per day in terms of catechin dry weight, preferably 50
About 0 to 1000 mg is preferable.
【0016】(ボランティア試験)本試験では、9名の
ボランティアに対し、テアフラン90Sを一粒当り120mg含
有する糖衣錠(カテキンタブレット)を一日に5錠摂取
してもらった。この結果、一日のテアフラン90Sの摂
取量は600mgとなり、テアフラン90Sのカテキン
成分含有量(重量%)から一日のカテキンの摂取量は下
記表1のようになる。(Volunteer Test) In this test, nine volunteers were ingested five sugar-coated tablets (catechin tablets) containing 120 mg of theafuran 90S per tablet daily. As a result, the daily intake of theafuran 90S is 600 mg, and the daily intake of the catechin is as shown in Table 1 based on the catechin component content (% by weight) of the theafuran 90S.
【0017】[0017]
【表1】 【table 1】
【0018】(採血と血液検査)カテキンタブレット飲
用前、及び飲用後2週間経過時点において、朝の空腹状
態で採血を行った。得られた血液は遠心分離にて血清を
採取し、血清総コレステロール、血清胆汁酸の測定を行
った。(Blood Sampling and Blood Test) Before taking the catechin tablet and two weeks after the drinking, blood was collected on an empty stomach in the morning. Serum was collected from the obtained blood by centrifugation, and serum total cholesterol and serum bile acids were measured.
【0019】[0019]
【表2】 [Table 2]
【0020】(結果及び考察)表2には、茶ポリフェノ
ールの血清胆汁酸に及ぼす影響に関する試験データを記
載した。この結果、比較的血清コレステロールの高いボ
ランティアに対しては、茶ポリフェノールの摂取によっ
て生体内で胆汁酸の生成が促進され、血清胆汁酸濃度が
高まることが判明した。また、正常な血清コレステロー
ル値を有するボランティアに対しては、茶ポリフェノー
ルは大きな変化は観察されなかった。(Results and Discussion) Table 2 shows test data on the effects of tea polyphenols on serum bile acids. As a result, it has been found that for volunteers having relatively high serum cholesterol, ingestion of tea polyphenol promotes bile acid production in vivo and increases serum bile acid concentration. In addition, no significant change in tea polyphenol was observed in volunteers having normal serum cholesterol levels.
【0021】(実施例1)茶抽出物を以下の割合で配合
し、胆汁酸生成促進効果のあるタブレットを作成した。Example 1 A tea extract was blended in the following ratio to prepare a tablet having a bile acid production promoting effect.
【0022】 茶抽出物(テアフラン90S又はテアフラン30A) … 120 mg ビタミンC … 50 mg 乳化オリゴ糖 … 90 mg 造粒剤 … 60 mg 結晶セルロース … 80 mg 還元麦芽糖水飴 … 90 mg スクロース … 100 mg 香料 … 適量Tea extract (Theafuran 90S or Theafuran 30A)… 120 mg Vitamin C… 50 mg Emulsified oligosaccharide… 90 mg Granulating agent… 60 mg Crystalline cellulose… 80 mg Reduced maltose syrup… 90 mg Sucrose… 100 mg Flavor… Appropriate amount
【0023】(実施例2)茶抽出物を以下の割合で配合
し、胆汁酸生成促進効果のある飲料を作成した。Example 2 A tea extract was blended in the following ratio to prepare a beverage having a bile acid production promoting effect.
【0024】 茶抽出物(テアフラン90S又はテアフラン30A) … 150 mg ビタミンC … 50 mg 果糖ぶどう液糖 … 10 g 水溶性食物繊維 … 500 mg 香料 … 適量 イオン交換水 … 100 mLに調整Tea extract (Theafran 90S or Theafuran 30A)… 150 mg Vitamin C… 50 mg Fructose grape sugar… 10 g Water-soluble dietary fiber… 500 mg Flavor… Appropriate amount Ion-exchanged water… adjusted to 100 mL
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 31/353 A61P 1/16 101 A61P 1/16 101 A23L 2/00 F (72)発明者 松井 輝明 東京都板橋区若木1−21−2−401 (72)発明者 今武 和弘 埼玉県富士見市鶴瀬西2−7 アルビス鶴 瀬2−902 (72)発明者 新橋 一彦 東京都練馬区豊玉中1−10−4 (72)発明者 高砂 憲一 東京都杉並区荻窪4−21−25−407 (72)発明者 佐藤 秀樹 東京都板橋区成増1−13−16−1103 (72)発明者 飯田 美世 東京都板橋区大谷口北町57−3−502 (72)発明者 山崎 英俊 東京都豊島区西池袋5−21−7−205 Fターム(参考) 4B017 LC03 LG14 LL09 LP01 4B018 LB08 LE05 MD59 MD60 ME14 MF01 4B027 FB01 FB08 FB10 FB13 FC06 FP72 FP85 4C086 BA08 NA14 ZA76 4C088 AB45 AC05 BA09 CA05 NA14 ZA76 ──────────────────────────────────────────────────の Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61K 31/353 A61P 1/16 101 A61P 1/16 101 A23L 2/00 F (72) Inventor Teruaki Matsui Tokyo 1-21-2-401, Wakagi, Itabashi-ku (72) Inventor Kazuhiro Imatake 2-7 Tsuruse Nishi, Fujimi-shi, Saitama Albis-Tsuruse 2-902 (72) Inventor Kazuhiko Shimbashi 1-10 Toyotamanaka, Nerima-ku, Tokyo -4 (72) Inventor Kenichi Takasago 4-21-25-407, Ogikubo, Suginami-ku, Tokyo (72) Inventor Hideki Sato 1-13-16-1103, Narimasu, Itabashi-ku, Tokyo (72) Inventor Miyo Iida, Itabashi, Tokyo 57-3-502, Otaniguchi-Kitacho, Ward (72) Inventor Hidetoshi Yamazaki 5-21-7-205 Nishiikebukuro, Toshima-ku, Tokyo F-term (reference) 4B017 LC03 LG14 LL09 LP01 4B018 LB08 LE05 MD59 MD60 ME14 MF01 4B027 FB01 FB08 FB10 FB1 3 FC06 FP72 FP85 4C086 BA08 NA14 ZA76 4C088 AB45 AC05 BA09 CA05 NA14 ZA76
Claims (4)
抽出物を有効成分として含有する胆汁酸生成促進剤。1. A bile acid production promoter comprising, as an active ingredient, a tea extract obtained by extracting tea with warm water or hot water.
ン、(-)-エピカテキンガレート、(-)-エピガロカテキン
ガレート、 (±)-カテキン、(-)-ガロカテキン、(-)-カ
テキンガレート、(-)-ガロカテキンガレート、テアフラ
ビン、テアルビジンのいずれか或いはこれらの2種類以
上を組み合わせて混合してなる茶ポリフェノールを有効
成分として含有する胆汁酸生成促進剤。(2) (-)-epicatechin, (-)-epigallocatechin, (-)-epicatechin gallate, (-)-epigallocatechin gallate, (±) -catechin, (-)-gallocatechin, (- A bile acid production promoter containing, as an active ingredient, a tea polyphenol obtained by mixing any one of-)-catechin gallate, (-)-gallocatechin gallate, theaflavin, and thearvidin, or a combination of two or more thereof.
抽出物を有効成分として含有する胆汁酸生成促進飲食
物。3. A bile acid production-promoting food or drink comprising, as an active ingredient, a tea extract obtained by extracting tea with warm or hot water.
ン、(-)-エピカテキンガレート、(-)-エピガロカテキン
ガレート、 (±)-カテキン、(-)-ガロカテキン、(-)-カ
テキンガレート、(-)-ガロカテキンガレート、テアフラ
ビン、テアルビジンのいずれか或いはこれらの2種類以
上を組み合わせて混合してなる茶ポリフェノールを有効
成分として含有する胆汁酸生成促進飲食物。(4) (-)-epicatechin, (-)-epigallocatechin, (-)-epicatechin gallate, (-)-epigallocatechin gallate, (±) -catechin, (-)-gallocatechin, ( A bile acid production-promoting food or beverage containing, as an active ingredient, a tea polyphenol obtained by mixing any one of-)-catechin gallate, (-)-gallocatechin gallate, theaflavin, and thearvidin, or a combination of two or more thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000120598A JP2001302529A (en) | 2000-04-21 | 2000-04-21 | Bile acid production promoter and food and drink |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000120598A JP2001302529A (en) | 2000-04-21 | 2000-04-21 | Bile acid production promoter and food and drink |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2001302529A true JP2001302529A (en) | 2001-10-31 |
Family
ID=18631382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000120598A Pending JP2001302529A (en) | 2000-04-21 | 2000-04-21 | Bile acid production promoter and food and drink |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2001302529A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006104213A (en) * | 2003-02-10 | 2006-04-20 | Ito En Ltd | Food and drink used for lowering serum cholesterol and method for producing the same |
| WO2007125644A1 (en) | 2006-04-26 | 2007-11-08 | Ito En, Ltd. | Fat absorption inhibitor |
| JP2008306980A (en) * | 2007-06-14 | 2008-12-25 | Mitsui Norin Co Ltd | Instant powder tea |
| US7829132B2 (en) * | 2004-11-03 | 2010-11-09 | Unilever Bestfoods, North America Division Of Conopco, Inc. | Consumable tea composition with antioxidants |
| US7862847B2 (en) | 2003-09-26 | 2011-01-04 | Kao Corporation | Packaged beverages containing β-cyclodextrin |
| WO2011105383A1 (en) | 2010-02-25 | 2011-09-01 | 富士フイルム株式会社 | Agent for controlling production of primary bile acid and secondary bile acid |
| CN118160835A (en) * | 2024-03-26 | 2024-06-11 | 南京农业大学 | A bile acid synthesis promoter and its preparation method and application |
-
2000
- 2000-04-21 JP JP2000120598A patent/JP2001302529A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006104213A (en) * | 2003-02-10 | 2006-04-20 | Ito En Ltd | Food and drink used for lowering serum cholesterol and method for producing the same |
| US7862847B2 (en) | 2003-09-26 | 2011-01-04 | Kao Corporation | Packaged beverages containing β-cyclodextrin |
| US7829132B2 (en) * | 2004-11-03 | 2010-11-09 | Unilever Bestfoods, North America Division Of Conopco, Inc. | Consumable tea composition with antioxidants |
| WO2007125644A1 (en) | 2006-04-26 | 2007-11-08 | Ito En, Ltd. | Fat absorption inhibitor |
| JP2008306980A (en) * | 2007-06-14 | 2008-12-25 | Mitsui Norin Co Ltd | Instant powder tea |
| WO2011105383A1 (en) | 2010-02-25 | 2011-09-01 | 富士フイルム株式会社 | Agent for controlling production of primary bile acid and secondary bile acid |
| CN118160835A (en) * | 2024-03-26 | 2024-06-11 | 南京农业大学 | A bile acid synthesis promoter and its preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014193178A (en) | Lipase activity inhibitor including macromolecular polyphenol fraction, tea extract, and method for manufacturing the same | |
| RU2697670C9 (en) | Pharmaceutical composition containing silybin and radix puerariae extract | |
| JP2007228964A (en) | Fermented tea leaves, fermented tea leaf extract and food and drink | |
| CN108391774A (en) | A kind of drinks of antigout and preparation method thereof | |
| CN101001535B (en) | Fermented tea obtained by kneading tea material leaves and loquat leaves, and composition containing extract contained in fermented tea as effective component | |
| CN106962934A (en) | A kind of alcohol-decomposing beverage based on Tea Saponin | |
| CN101683165B (en) | Composition for restraining rise of blood glucose and food and drink using these | |
| CN102686231A (en) | Liver function enhancer composition | |
| CN101766274B (en) | Antioxidant functional food composition containing bamboo leaf flavonoids | |
| JP3621517B2 (en) | Anti-allergy / anti-inflammatory agents and anti-allergy / anti-inflammatory foods | |
| JP2001302529A (en) | Bile acid production promoter and food and drink | |
| JPH10508880A (en) | Pharmaceutical composition for diabetes | |
| JP4317781B2 (en) | Beverage containing catechins in containers | |
| CN102596214B (en) | Composition for improving fatty liver | |
| RU2435450C1 (en) | Biologically active dietary supplement origitea® ochischeniye vecher | |
| CN113749203A (en) | Beverage with weight reducing effect and preparation method thereof | |
| JP3130327B2 (en) | Liver dysfunction preventive agent and functional food having hepatic dysfunction preventive action | |
| US20240123019A1 (en) | Composition for treating or ameliorating liver disease and liver dysfunction comprising zizania latifolia extract | |
| JP2002524419A (en) | Compositions for improving mental performance in mammals | |
| JP2018168144A (en) | Lipase inhibitors and uses thereof | |
| US9737583B2 (en) | Composition for prevention or treatment of acute renal failure including herbal extract or fraction thereof as active ingredient | |
| KR100696589B1 (en) | Hangover Relief and Liver Protection Compositions Containing Catechin Constituents | |
| CN104738775A (en) | Plant beverage and preparation technology thereof | |
| KR20210041387A (en) | A natural tea removing the effect of hangover contained the extract material in arrowroot blossoms and Plantago ovata | |
| JP7350304B2 (en) | Allergic rhinitis symptom suppressant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070213 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070405 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070508 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070709 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070709 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070807 |